Search

Your search keyword '"Liu, Chia-Jen"' showing total 1,339 results

Search Constraints

Start Over You searched for: Author "Liu, Chia-Jen" Remove constraint Author: "Liu, Chia-Jen"
1,339 results on '"Liu, Chia-Jen"'

Search Results

51. Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice

62. Prognostic role of circulating exosomal miRNAs in multiple myeloma

63. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

65. Prompt successful response to a COVID-19 outbreak: Performance of community-based rapid screening station

68. Supplementary Data from Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications

69. Supplementary Figures S1-2, Tables S1-3 from Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors

70. Data from Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

71. Supplementary Methods, Figure Legends, Figures 1 - 9, Tables 1 - 8 from Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma

72. Supplementary Figures 1-3 from Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

81. Data from Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms

82. Fig S6 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation

83. Supplementary Figure S8 from Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts

84. Supplementary Table 1 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation

85. Supplementary Data 3 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

86. Supplementary Data from Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms

88. Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

89. Table S1 from Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts

90. Supplementary Methods from Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts

91. Supplementary Methods and References from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

92. Data from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

93. Supplementary Figures S1-S5 from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

94. Supplementary Figure Legends from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

95. Supplementary Tables S1-S4 from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

96. Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance

98. Long‐term outcomes of frontline intensification in primary CNS lymphoma: A real‐world single‐center experience

Catalog

Books, media, physical & digital resources